Expeditious synthesis of chiral 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazines
摘要:
An expeditious one-pot two-step synthesis of chiral 4-substituted-6-methyl-1,2-dihydropyrrolo[1,2-a]pyrazin-3(4H)-ones via reaction between 5-methyl furfurylamine and N-Boc amino acids is described. LiAlH4-mediated reduction of 4-substituted-6-methyl-1,2-dihydropyrrolo[1,2-a]pyrazin-3(4H)-ones affords respective chiral 1,2,3,4-tetrahydropyrrolo[1,2-c]pyrazines in excellent yields. (C) 2013 Elsevier Ltd. All rights reserved.
Pyrazolopyrimidines, a process for their preparation and their use as medicine
申请人:Merz Pharma GmbH & Co. KGaA
公开号:EP2085398A1
公开(公告)日:2009-08-05
The invention relates to pyrazolopyrimidine derivatives of Formula I
wherein
R1 represents chloro or bromo;
A represents
as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
申请人:Merz Pharma GmbH & Co. KGaA
公开号:EP2090576A1
公开(公告)日:2009-08-19
The invention relates to 6-halo-pyrazolo[1,5-a]pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
wherein A represents -NR3R4
with R3 and R4 as described herein.
Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.